🧬 BioMed Pulse · 2026-06-23 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses, and New Cures

Monday, June 23, 2026 | Edition 174

⚡ TL;DR

The Bundibugyo Ebola virus outbreak in DRC and Uganda has now reached 896 confirmed cases and 232 deaths as of June 17, remaining a WHO-declared Public Health Emergency of International Concern - the dominant global health story this week. ^[1]

Mood: Urgent on hemorrhagic fever; cautiously watchful on food safety and aging biology as summer deepens.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA - DRC AND UGANDA (ACTIVE PHEIC)

• As of June 17, 2026, 896 confirmed cases including 232 deaths have been reported from the Democratic Republic of the Congo, with cross-border transmission continuing into Uganda. ^[1]
• WHO declared the Bundibugyo virus disease (BVD) outbreak a Public Health Emergency of International Concern on May 17, 2026; the IHR Emergency Committee confirmed it does not yet meet the criteria for a pandemic emergency. ^{[2] [3]}
• Africa CDC and WHO jointly launched a continental preparedness and response plan on June 5, aiming to raise USD 518 million to support African countries in the response. ^[4]
• WHO issued its first comprehensive clinical management guidelines covering all Ebola and Marburg filovirus types on June 17, directly in response to this outbreak. ^[5]
• WHO convened expert groups in late May to assess candidate vaccines and therapeutics specifically against Bundibugyo virus, for which no licensed vaccine currently exists. ^[6]
• CDC activated enhanced Ebola airport screening at Washington-Dulles International Airport on May 21 and expanded it to Atlanta on May 23; CDC is also running a joint World Cup 2026 activation briefing given mass gathering risk. ^{[7] [8] [9]}

ANDES HANTAVIRUS - CRUISE SHIP M/V HONDIUS (RESOLVING)

• The fourth WHO Disease Outbreak News report confirmed the pathogen aboard M/V Hondius is Andes hantavirus; as of the May 28 update, additional confirmed cases had been identified beyond the initial cluster of 8 cases and 3 deaths reported on May 7. ^[10]
• Over 120 passengers from 23 countries were safely disembarked in Tenerife, Spain; WHO Director-General Tedros personally addressed the people of Tenerife to express gratitude for their cooperation during the operation.
• CDC characterized the ongoing risk to the American public as extremely low as of mid-May 2026.

MPOX - CLADE I AND RECOMBINANT STRAINS

• A WHO Disease Outbreak News report from December 2025 flagged local transmission of clade Ib monkeypox virus (MPXV) among men who have sex with men in countries not previously affected, beyond the original DRC epicenter.
• A February 2026 WHO DON described two documented cases of a recombinant MPXV strain carrying genomic elements of both clade Ib and clade IIb, a naturally occurring but newly observed event with unknown clinical implications.

NIPAH VIRUS - INDIA AND BANGLADESH

• On January 26, 2026, India notified WHO of two laboratory-confirmed Nipah virus (NiV) infections in healthcare workers at a private hospital in Barasat, West Bengal; virus confirmed at the National Institute of Virology.
• On February 3, 2026, Bangladesh reported one confirmed NiV case in Rajshahi Division; the patient developed fever and neurological symptoms on January 21 with laboratory confirmation following.

MERS-COV - ONGOING SURVEILLANCE

• A WHO global update through December 21, 2025 reported 19 MERS-CoV cases including 4 deaths in 2025, with 17 from Saudi Arabia and 2 from France; no evidence of sustained human-to-human transmission was noted.

AVIAN INFLUENZA A(H9N2) - ITALY

• Italy notified WHO on March 21, 2026 of one human A(H9N2) case in an adult male returning from Senegal; next-generation sequencing confirmed the subtype, with no evidence of onward transmission.

MEASLES - BANGLADESH AND GLOBAL SURGE

• Bangladesh reported a nationwide measles surge as of April 4, 2026, with 19,161 suspected cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in all eight divisions.
• Globally, measles infected 10.3 million people in 2023 according to CDC-WHO joint reporting, representing a significant resurgence.

FOOD-BORNE OUTBREAKS - U.S. (CURRENT)

• CDC warns of a Listeria outbreak linked to recalled chicken fettuccine alfredo meals, with 17 people sickened from the same strain as of June 19, 2026.
• CDC warns of a Listeria outbreak linked to requesón and soft ricotta cheese, issued June 5, 2026; consumers urged to check products.
• Salmonella linked to pistachio cream has sickened four people with the same strain as of June 16, 2026.
• A Salmonella outbreak tied to eggs was reported by CDC on June 7, 2026, with a multistate investigation underway.

NEW WORLD SCREWWORM - EMERGENCY RESPONSE

• CDC activated its Emergency Operations Center on June 12, 2026 for a New World Screwworm (Cochliomyia hominivorax) response, a parasitic fly capable of infesting living tissue in humans and animals.

DRUG-RESISTANT BACTERIA - SHARP RISE

• A September 2025 CDC report found a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing antimicrobial resistance as a growing public health threat.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE AND KIDNEY REPAIR

• A June 14, 2026 Europe PMC study found that AMD1-mediated polyamine metabolism in tubular cells governs whether kidneys repair normally or enter senescence after acute injury - blocking senescence could be a target for preserving kidney function with age.

TELOMERE LENGTH, DNA METHYLATION, AND BRAIN ANEURYSMS

• Genetic analysis published May 30, 2026 linked DNA methylation-estimated biological age phenotypes and shorter telomere length to increased risk of intracranial aneurysms, adding vascular aging to the growing list of telomere-associated disease risks.

HANDGRIP STRENGTH AND DIGESTIVE DISEASE RISK IN OLDER ADULTS

• A prospective study in Chinese and European older adults published June 15, 2026 found that combined handgrip strength is inversely associated with incident chronic digestive diseases, suggesting muscle function is a practical aging biomarker beyond cardiovascular disease.

COLLAGEN OXIDATION AND TISSUE AGING

• A June 11, 2026 paper described both enzymatic and non-enzymatic oxidation of fibrillar collagen, processes that stiffen the extracellular matrix over time and drive tissue-level aging in skin, bone, and connective tissue.

GUT MICROBIOME, PREBIOTICS, AND JOINT HEALTH IN OBESITY

• A June 2026 Gut Microbes study found that prebiotic supplementation modified gut microbiome composition and improved physical function and metabolism in obese adults with knee osteoarthritis, pointing to a gut-joint axis relevant to age-related mobility decline.

MATERNAL DIET AND NEONATAL MICROBIOME RESILIENCE

• Research published June 9, 2026 in Gut Microbes demonstrated that maternal diet shapes neonatal microbiome development and neurometabolic resilience in early life, with implications for long-term health programming from birth.

REPRODUCTIVE AGING AND DELAYED CHILDBEARING

• A narrative review published June 9, 2026 in the Journal of Obstetrics and Gynaecology examined how delayed childbearing intersects with accelerating reproductive aging, including ovarian reserve decline and uterine aging mechanisms.

URIC ACID, FERROPTOSIS, AND NEURODEGENERATION

• A June 4, 2026 study showed that uric acid alleviates neuroinflammation in a mouse model of Parkinson's disease by resisting ferroptosis via the Nrf2 signaling pathway, suggesting a protective role for controlled uric acid levels in aging neurons.

HIGH-ALTITUDE CHRONIC HYPOXIA AND NEURODEGENERATION

• A new multicenter observational cohort study posted June 22, 2026 on ClinicalTrials.gov (HANC Study, NCT07657520) is investigating whether chronic physiological hypoxia at high altitude contributes to multiple system atrophy, a fatal neurodegenerative disorder of unknown cause.

COOKING, DIET PATTERN, AND DEMENTIA PREVENTION TRIAL

• A trial posted June 22, 2026 (NCT07661368) is testing whether DASH-diet-based cooking education can prevent dementia and type 2 diabetes by reducing ultra-processed food consumption, based on prior research linking UPF intake to cognitive impairment in later life.

💊 NEW CURES & APPROVALS

• SKYRIZI (risankizumab-rzaa) by AbbVie received supplemental approvals under two BLA numbers (BLA761262 and BLA761105), the IL-23-targeting biologic already indicated for plaque psoriasis, psoriatic arthritis, and Crohn's disease.
• KEYTRUDA (pembrolizumab) by Merck Sharp and Dohme received a supplemental approval (BLA125514), continuing the PD-1 checkpoint inhibitor's expansion across multiple oncology indications.
• WELIREG (belzutifan) by Merck Sharp and Dohme received a supplemental approval (NDA215383); belzutifan is a HIF-2 alpha inhibitor used in VHL disease-associated tumors and renal cell carcinoma.
• RINVOQ LQ (upadacitinib) by AbbVie received a supplemental approval (NDA218347); upadacitinib is a JAK1-selective inhibitor used in rheumatoid arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.
• TZIELD (teplizumab-mzwv) by Provention Bio received a supplemental approval (BLA761183); teplizumab is a CD3-directed antibody that delays onset of Stage 3 type 1 diabetes.
• REXTOVY (naloxone hydrochloride) by Amphastar Pharmaceuticals received a supplemental approval (NDA208969), supporting expanded access to opioid overdose reversal.
• PERAMPANEL by Taro received an original approval (ANDA219052) for this AMPA-receptor antagonist used in epilepsy.
• LACOSAMIDE by Prod Development received an original generic approval (ANDA217596) for this sodium-channel-modulating antiepileptic.
• BOSUTINIB MONOHYDRATE by Alembic received a supplemental tentative approval (ANDA209543) for this BCR-ABL tyrosine kinase inhibitor used in chronic myelogenous leukemia.

🧪 CLINICAL TRIALS

DEMENTIA PREVENTION THROUGH DASH COOKING

• Trial NCT07661368, posted June 22, 2026, tests whether structured DASH-diet cooking education reduces ultra-processed food intake and lowers dementia and type 2 diabetes risk; based on Seago et al. 2025 data linking UPF consumption to cognitive impairment.

COGNITIVE-BASED BALANCE REHABILITATION IN PARKINSON'S DISEASE

• NCT07660978, posted June 22, 2026, is a randomized single-blind trial comparing immersive virtual reality versus dual-task training for balance, gait, and cognition in Parkinson's disease patients.

HIGH-ALTITUDE NEURODEGENERATION COHORT - MULTIPLE SYSTEM ATROPHY

• NCT07657520, posted June 22, 2026, is a Phase II multicenter observational cohort study investigating chronic hypoxia as a risk factor for multiple system atrophy, a fatal neurodegenerative disorder of unknown etiology.

JOINT SUPPLEMENT FOR KNEE OSTEOARTHRITIS IN MIDDLE-AGED ADULTS

• NCT07658950, posted June 22, 2026, is testing INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT in adults aged 40 to 60 years with mild symptomatic knee osteoarthritis, using WOMAC and VAS pain scores as endpoints.

INTRANASAL SARS-COV-2 VACCINE TRIAL

• NCT07536308, posted June 22, 2026, is a Phase 1 randomized open-label dose-escalation trial of OCU500, a ChAd36 vector encoding the SARS-CoV-2 spike protein delivered intranasally and via inhalation, in previously vaccinated adults aged 18 to 64.

PROSTATE CANCER IMMUNOTHERAPY ON ACTIVE SURVEILLANCE

• NCT07574541, posted June 22, 2026, is testing a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine combined with IL-15 superagonist N-803 in men with localized prostate cancer on active surveillance, where 35 percent will require treatment within 5 years.

LASER ACUPUNCTURE FOR TYPE 2 DIABETES AND BODY COMPOSITION

• NCT07661160, posted June 22, 2026, is testing whether laser acupuncture improves A Body Shape Index and metabolic outcomes in women with type 2 diabetes.

KETOCONAZOLE FOR MILD AUTONOMOUS CORTISOL SECRETION

• NCT07649317, posted June 22, 2026, is investigating whether ketoconazole can normalize the daily cortisol rhythm in patients with MACS, a condition causing excess cortisol linked to hypertension, diabetes, and weight gain.

📢 PUBLIC HEALTH

ACIP MEETING CONCLUDES - JUNE 25-26, 2025

• CDC's Advisory Committee on Immunization Practices concluded its June 25 to 26, 2025 meeting with a joint statement; agenda and presentations are posted online by CDC.

CDC IMMUNIZATION SCHEDULE UPDATES - COVID-19 AND VARICELLA

• In October 2025, CDC updated adult and child immunization schedules to apply individual-based decision-making for COVID-19 vaccination and to allow standalone varicella vaccination for toddlers.

HEPATITIS B VACCINE - INDIVIDUAL-BASED DECISION-MAKING FOR INFANTS

• Effective December 16, 2025, CDC adopted individual-based decision-making for hepatitis B immunization for infants born to women who test negative for hepatitis B virus, following an ACIP vote on December 5, 2025.

PNEUMOCOCCAL VACCINATION AGE LOWERED TO 50

• In October 2024, CDC Director Mandy Cohen endorsed the ACIP recommendation to lower the recommended age for pneumococcal vaccination from 65 to 50 years old.

INFANT BOTULISM LINKED TO FORMULA - ONGOING INVESTIGATION

• CDC issued an outbreak update on June 13, 2026 urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, linked to infant botulism cases.

UNSAFE FOOD CAUSES 866 MILLION ILLNESSES ANNUALLY - WHO

• WHO released new estimates on June 3, 2026 showing unsafe food causes 866 million illnesses and 1.5 million deaths per year globally, with children under five facing almost three times the illness risk of older individuals.

SALMONELLA - BACKYARD POULTRY UPDATE

• A May 14, 2026 CDC update reported 150 additional Salmonella illnesses linked to backyard poultry, with over a quarter of all cases in children under 5 years old across 13 states.

U.S. DRUG OVERDOSE DEATHS DOWN 27 PERCENT

• Provisional 2024 data from CDC's National Vital Statistics System showed a 27 percent decrease in drug overdose deaths in the United States, continuing a significant downward trend from the 2023 figure of nearly 24 percent.

WHO PANDEMIC AGREEMENT - PATHOGEN ACCESS ANNEX PENDING

• WHO Director-General Tedros, in an open letter dated June 15, 2026 to leaders of the G7, G20, BRICS and all nations, urged finalizing the Pathogen Access and Benefit Sharing annex of the WHO Pandemic Agreement, describing it as unfinished essential work for global health security.

U.S. COMPLETES WHO WITHDRAWAL

• The United States formally completed its withdrawal from the World Health Organization, effective January 22, 2026, citing COVID-19 failures, politicization, and a stated shift to bilateral health efforts.

This briefing is informational only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
2. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
3. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
5. WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease — WHO News
6. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
7. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
9. Transcript - Update on Ebola Outbreak in the Democratic Republic of the Congo and Uganda and CDC's World Cup 2026(TM) ac — CDC Newsroom
10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260623-02-v9 · 2026-06-23 02:02 UTC